Punk Ziegel Starts Indevus Pharmaceuticals (IDEV) at Buy
More News related to IDEV
- Endo Pharma (ENDP) Extends Period of Tender Offer for Shares of Indevus (IDEV)
- Indevus Pharma (IDEV) Announces NIH-Sponsored Study on PRO 2000 Shows Promise in HIV Prevention
- JMP Downgrades Indevus Pharma (IDEV) to Market Perform
- UBS Downgrades Indevus Pharmaceuticals (IDEV) to Neutral
- Unusual 11 Mid-Day Movers 1/6: IDEV, TXCO, ARM, ALD Higher; VDSI, CTDC, SMCI, ENDP Lower
More News related to New Coverage
- Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
- Credit Suisse Resumes Coverage on Rio Tinto (RTP) with an Outperform
Punk Ziegel initiates coverage on Indevus Pharmaceuticals Inc. (Nasdaq: IDEV) with a Buy rating and $11 price target. Analyst Juan Sanchez, MD said, "Although Indevus currently has a modest presence in the urology and endocrinology markets, the basis for our positive recommendation is derived from two late-stage drugs, Sanctura XR and Nebido, with best-in-class potential and the pending acquisition of Valera Pharmaceuticals."
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
